Legend: 
= Applied Session,
= Theme Session,
= Presenter, Sheraton Seattle Hotel & Towers = “S”
Washington State Convention & Trade Center = “CC”, Grand Hyatt Seattle = “H”
|
|
|
|
|
|
161
|
Mon, 8/7/06, 12:30 PM - 1:50 PM
|
CC-4C-2
|
|
Biopharmaceutical Section Roundtables with Lunch (fee event) - Roundtable Lnch
|
Biopharmaceutical Section
|
|
Organizer(s): Amit Bhattacharyya, GlaxoSmithKIine
|
|
ML09:
|
New Development and Challenges in Phase I and Phase I/II Dose-Finding Studies —  Weili He, Merck & Co., Inc.
|
|
ML10:
|
Analysis and Evaluation of Safety Information from Clinical Trial Data — H. Amy Xia, Amgen Inc.
|
|
ML11:
|
Time-to-Event Analysis with Uncertain Endpoints — Li Chen, Amgen Inc.
|
|
ML12:
|
Analyses of Stratified Trials: Tips for Improving Power — Devan V. Mehrotra, Merck Research Laboratories
|
|
ML13:
|
CANCELLED - Using Computer Simulation To Aid in Dose Selection in Clinical Trials — Kenneth Liu, Merck & Co., Inc.
|
|
ML14:
|
Assessing the Concordance of Two-Measurement Methods — Jason Liao, Merck Research Laboratories
|
|
ML15:
|
CANCELLED - Pharmacogenomics for Drug Development and Personalized Medicine — Xuejun Peng, Takeda Global Research and Development Center
|
|
ML16:
|
CANCELLED - What To Do with Interaction Effects at Interim Analysis? — Yuko Palesch, Medical University of South Carolina
|
|
ML17:
|
Preparation of Interim Reports for Independent Data Monitoring Committee Review — KyungMann Kim, University of Wisconsin-Madison
|
|
ML18:
|
Statistical Design and Analysis Issues Associated with the Establishment of the Safety and Effectiveness of Medical Devices — Gary Kamer, U.S. Food and Drug Administration
|
|
ML19:
|
Issues in Planning Two-Arm Clinical Trials of Active Drugs — Sheela Talwalker, T'Walker Consulting
|
|
ML20:
|
Analysis of Multiple Failure Outcomes — Guowen Sun, sanofi-aventis
|
|
ML21:
|
What Are the Statistical Issues in Subgroup Analysis - Design, Analysis, and Interpretation? — Chul H. Ahn, U.S. Food and Drug Administration
|
|
ML22:
|
Conducting Multiple Event Analysis in Clinical Trials — Xiang Zhang, Amgen Inc.
|
| |
